Semaglutide Oral Tablet

DRUG3 trials

Sponsors

University Medical Centre Ljubljana, University of Oxford, Institute of Liver and Biliary Sciences, India

Conditions

AtherosclerosisChronic Kidney DiseasesDiabetes Mellitus, Type 2MAFLD

Phase 4

A Study of Cardiovascular Events iN Diabetes Plus

Active, not recruitingNCT05441267

University of OxfordDiabetes Mellitus, Type 2

Start: 2023-03-13End: 2048-08-17Updated: 2026-06-23

Unknown Phase

Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients

University Medical Centre LjubljanaAtherosclerosis, Diabetes Mellitus, Type 2

Start: 2022-05-01End: 2023-12-01Target: 100Updated: 2022-05-24

Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

Not yet recruitingNCT07391267

Institute of Liver and Biliary Sciences, IndiaChronic Kidney Diseases, MAFLD

Start: 2026-02-01End: 2028-12-31Target: 90Updated: 2026-02-05

Related Papers

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).

2022-03-0817 citations